Saltar al contenido
Merck

F1308

Sigma-Aldrich

Fosinopril sodium

≥98% (HPLC), powder

Sinónimos:

(2S,4S)-4-Cyclohexyl-1-(2-{[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylic acid, Acecor, Eosinopril, Fosinopril, Monopril, SQ 28555, Secorvas, Staril

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C30H45NO7P · Na
Número de CAS:
Peso molecular:
585.64
Número MDL:
Código UNSPSC:
12352200
ID de la sustancia en PubChem:
NACRES:
NA.77

Nivel de calidad

Ensayo

≥98% (HPLC)

Formulario

powder

condiciones de almacenamiento

desiccated

color

white to off-white

solubilidad

H2O: >20 mg/mL

emisor

Bristol-Myers Squibb

temp. de almacenamiento

−20°C

cadena SMILES

O=C([O-])[C@H]1N(C(CP(CCCCC2=CC=CC=C2)(O[C@@H](C(C)C)OC(CC)=O)=O)=O)C[C@H](C3CCCCC3)C1.[Na+]

InChI

1S/C30H46NO7P.Na/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24;/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35);/q;+1/p-1/t25-,26+,30+,39?;/m1./s1

Clave InChI

TVTJZMHAIQQZTL-TXDYNIFHSA-M

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

Fosinopril lowers blood pressure and functions as an antihypertensive agent. It is an ester prodrug. Fosinopril is metabolised by the liver and excreted from the body by liver and kidney. It is used to treat heart failure.

Acciones bioquímicas o fisiológicas

Fosinopril is an angiotensin converting enzyme (ACE) inhibitor.
Fosinopril is an angiotensin converting enzyme (ACE) inhibitor. Fosinopril is also known to inhibit the activity of the peptide transporter PEPT2.

Características y beneficios

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogramas

Health hazardExclamation mark

Palabra de señalización

Warning

Frases de peligro

Clasificaciones de peligro

Eye Irrit. 2 - Repr. 2

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Disposition of fosinopril sodium in healthy subjects
Singhv SM, et al.
British Journal of Clinical Pharmacology, 25(1), 9-15 (1988)
Dinesh Shrikrishna et al.
Chest, 146(4), 932-940 (2014-02-22)
Skeletal muscle impairment is a recognized complication of COPD, predicting mortality in severe disease. Increasing evidence implicates the renin-angiotensin system in control of muscle phenotype. We hypothesized that angiotensin-converting enzyme (ACE) inhibition would improve quadriceps function and exercise performance in
S Giovannini et al.
The journal of nutrition, health & aging, 14(6), 457-460 (2010-07-10)
The present study evaluates the effects of a 6-month treatment with an ACE-inhibitor (ie, fosinopril) on serum concentrations of total IGF-1 and IGF binding protein (IGFBP)-3 in older adults at high risk for cardiovascular disease. Data are from the Trial
Ya-chen Zhang et al.
Cell biochemistry and biophysics, 64(3), 205-211 (2012-06-26)
Fosinopril, an angiotensin-converting enzyme inhibitor, is known to attenuate cardiomyopathy induced by doxorubicin (DOX); however, the mechanisms of this cardioprotection are not fully elucidated yet. In the present study, experimental cardiomyopathy was induced in rats by administration of DOX with
Patrick Rossignol et al.
Hypertension (Dallas, Tex. : 1979), 60(2), 339-346 (2012-07-11)
Optimal blood pressure (BP) targets are still controversial in end-stage renal disease. Recent data have highlighted shortcomings of the usual BP hypothesis in other patient populations and emphasized the importance of visit-to-visit variability of BP in predicting cardiovascular events. The

Artículos

We offer many products related to angiotensin receptors for your research needs.

We offer many products related to angiotensin receptors for your research needs.

We offer many products related to angiotensin receptors for your research needs.

We offer many products related to angiotensin receptors for your research needs.

Ver todo

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico